Dabrafenib is a small‑molecule drug that targets a specific mutation in the B‑RAF protein, a key player in cell‑division signaling. It’s mainly used in oncology, but you’ll also find it discussed in research about other cancers and even non‑cancer conditions. Below is a quick but thorough rundown—feel free to ask follow‑up questions if anything is unclear!
---
1. What is it and how does it work?
- Mechanism of action: Dabrafenib is a selective B‑RAF inhibitor. It blocks the kinase activity of the mutant B‑RAF V600E protein, preventing downstream MEK/ERK signaling that drives tumor growth.
- Why V600E? The V600E mutation substitutes valine with glutamic acid at position 600, causing constitutive activation of B‑RAF. Inhibiting this mutant specifically spares normal B‑RAF signaling, which helps reduce toxicity.
---
2. Approved indications (as of 2024)
| Cancer type | FDA‑approved use | Typical regimen |
|-------------|------------------|-----------------|
| Malignant melanoma (B‑RAF V600E/K) | Dabrafenib + trametinib combo | 150 mg twice daily (oral) |
| Metastatic or unresectable NRAS‑mutant melanoma | Dabrafenib alone | 150 mg twice daily |
| Locally advanced or metastatic renal cell carcinoma (B‑RAF V600E) | Dabrafenib + trametinib combo | 150 mg twice daily |
| Metastatic colorectal cancer (B‑RAF V600E) | Dabrafenib + encorafenib + cetuximab (triplet) | Dabrafenib 150 mg twice daily |
| Locally advanced or metastatic thyroid cancer (B‑RAF V600E) | Dabrafenib + trametinib | 150 mg twice daily |
| Other investigational uses | (e.g., glioblastoma, sarcoma) | Under clinical trial protocols |
Tip: The 150 mg BID dosing is standard, but dosages can be adjusted in special populations (e.g., renal/hepatic impairment).
---
3. How is it taken?
- Route: Oral tablet.
- Form: 75 mg or 150 mg tablets (usually 75 mg × 2 tablets = 150 mg BID).
- Timing: Take with food to improve absorption; consistent timing helps maintain plasma levels.
- Missed dose: If you forget a dose, take it as soon as you remember—do not double‑dose to catch up.
---
4. What are the common side effects?
| System | Typical adverse events | Management tips |
|--------|-----------------------|-----------------|
| Dermatologic | Rash, photosensitivity, pruritus, hyperpigmentation | Use broad‑spectrum sunscreen, wear protective clothing, monitor skin changes. |
| Cardiovascular | Hypertension, QT prolongation, reduced ejection fraction | Baseline and periodic blood pressure checks; ECG monitoring for QTc; avoid QT‑prolonging meds. |
| Hepatic | Elevated AST/ALT, bilirubin | Check LFTs before therapy and periodically; hold drug if severe elevation. |
| GI | Nausea, vomiting, diarrhea, constipation | Use antiemetics, antidiarrheals, and adequate fluids. |
| Other | Fever, chills, myalgia, fatigue, headache, arthralgia | Symptomatic treatment; dose hold if severe. |
Rare but serious: Tumor‑shattering syndrome, severe cutaneous adverse reactions (SJS/TEN), interstitial lung disease.
---
5. Drug interactions
- CYP2C19/CYP3A4 inducers (e.g., carbamazepine, rifampicin) → lower dabrafenib levels → consider dose adjustment or avoid.
- CYP2C19 inhibitors (e.g., omeprazole, fluconazole) → increase levels → monitor for toxicity.
- QT‑prolonging agents (e.g., quinidine, azithromycin, ondansetron) → additive effect → avoid or monitor QTc.
- Anticoagulants: Dabrafenib can affect coagulation; monitor INR if on warfarin.
- Other kinase inhibitors: Concomitant use may increase toxicity (e.g., trametinib combo).
Pro tip: Check the most recent drug‑interaction table in the prescribing information, as updates happen.
---
6. Special populations
| Population | Considerations |
|------------|----------------|
| Renal impairment | Dabrafenib is predominantly hepatically cleared; no major dose adjustment for mild–moderate CKD. |
| Hepatic impairment | Mild (Child‑Pugh A) – no adjustment. Moderate (B) – consider 50 % reduction. Severe (C) – not recommended. |
| Pregnancy | Category D; animal studies show fetal harm. Avoid if possible; use effective contraception. |
| Breastfeeding | Drug detected in breast milk; discontinue breastfeeding. |
| Children | Not approved for pediatric use; investigational trials only. |
---
7. Pharmacokinetics (quick snapshot)
- Bioavailability: ~40 % after oral dose; food increases absorption.
- Peak concentration (Tmax): 2–4 h post‑dose.
- Half‑life: ~6–7 h (steady‑state ~24 h with BID dosing).
- Metabolism: Primarily via CYP2C19 and CYP3A4; minor CYP2D6.
- Elimination: Mainly fecal (≈70 %) and urinary (≈10 %).
---
8. Practical tips for patients and caregivers
1. Set a daily reminder: Consistency keeps drug levels stable.
2. Track side effects: Keep a simple log—rash, fever, GI upset, etc.—to share with your oncologist.
3. Watch for signs of serious toxicity: Severe skin lesions, chest pain, shortness of breath, high fever—call your doctor immediately.
4. Avoid sun exposure: Use SPF ≥ 30, reapply every 2 h, wear a hat/long sleeves.
5. Maintain a balanced diet: Helps with nausea/vomiting; discuss any dietary restrictions with your team.
---
9. Common questions
| Question | Short answer |
|----------|--------------|
| Can I drink alcohol? | Limit alcohol; it can increase liver toxicity. |
| Will this affect my fertility? | Potentially; discuss sperm preservation if needed. |
| Can I take it with other cancer drugs? | Often used with trametinib; avoid other kinase inhibitors unless supervised. |
| What if I develop a rash? | Report it immediately; you may need dose interruption or steroids. |
---
Bottom line
Dabrafenib is a powerful, mutation‑specific therapy that has transformed the outlook for many patients with B‑RAF V600E‑driven cancers. Its effectiveness depends on strict adherence, vigilant monitoring for side effects, and careful coordination with the broader drug regimen.
Got more specific questions? Whether you’re a patient, caregiver, or healthcare professional looking for deeper details—just let me know!